Colorectal adenocarcinoma
RecruitingSafety, Dose‑Finding and Feasibility Study of CD30/CEA CART in Patients with Liver Metastases from CEA‑Positive Colorectal Cancer
Safety, Dose‑Finding and Feasibility Study of CD30/CEA CART in Patients with Liver Metastases from CEA‑Positive Colorectal Cancer
- Disease:Colorectal adenocarcinoma
- Substances:AUTOLOGOUS T CELLS GENETICALLY MODIFIED TO EXPRESS A CHIMERIC ANTIGEN RECEPTOR DIRECTED AGAINST CD30 AND CEA
Germany- Participants:18–64 years · 65+ years
- Substances:AUTOLOGOUS T CELLS GENETICALLY MODIFIED TO EXPRESS A CHIMERIC ANTIGEN RECEPTOR DIRECTED AGAINST CD30 AND CEA
- Sponsor:Universitaetsklinikum Regensburg AöR
